You are viewing: Canada Oral Proteins & Peptides Market analysis

The Canada Oral Proteins & Peptides Market was valued at $88.2 Million in 2025 and projected to reach to $116.8 Million by 2030, representing a compound annual growth rate of 5.8%. Canada's oral proteins & peptides market is poised for steady growth driven by increasing healthcare expenditure, rising prevalence of chronic diseases, and growing consumer awareness of peptide-based therapeutics.

Canada Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada Oral Proteins & Peptides Market Trends and Insights

  • This moderate but steady expansion reflects Canada's mature healthcare infrastructure and increasing adoption of oral peptide therapeutics across pharmaceutical and nutraceutical sectors.
  • Canada's regulatory environment and strong pharmaceutical manufacturing base support the development and commercialization of innovative oral protein and peptide formulations. The Canadian market benefits from rising healthcare expenditure, growing prevalence of chronic diseases, and heightened consumer awareness of peptide-based treatments.
  • Canada's position within North America and its alignment with international regulatory standards position it as a key market for oral protein and peptide innovation.
  • Between 2025 and 2030, Canada is expected to see incremental market penetration driven by advances in bioavailability enhancement technologies and expanding clinical applications..

Key Market Statistics

  • CAGR (2025-2030) 5.8% CAGR
  • Market Size, 2025 ~USD 88.2 Million
  • Forecast, 2030 ~USD 116.8 Million
  • Country Canada

Canada Oral Proteins & Peptides Market Overview

Market Valuation :

Canada's oral proteins & peptides market is valued at $88.2 million in 2025, with projected growth to $116.8 million by 2030, demonstrating steady expansion in this therapeutic segment.

Regulatory Advantage :

Canada's Health Canada regulatory framework provides a streamlined pathway for oral peptide therapeutics approval, attracting pharmaceutical companies and supporting faster market entry compared to other regions.

Healthcare Infrastructure :

Canada's mature healthcare system and universal coverage model drive consistent demand for innovative oral peptide treatments, with strong adoption across both pharmaceutical and nutraceutical sectors.

Growth Trajectory :

With a CAGR of 5.8% through 2030, Canada's market reflects moderate but sustainable growth, positioning it as a stable investment opportunity within North America's oral peptide therapeutics landscape.

Canada Oral Proteins & Peptides Market Dynamics

  • The country's robust pharmaceutical infrastructure and favorable regulatory environment continue to attract investment from both domestic and international players seeking to develop and commercialize innovative oral formulations. The Canadian market benefits from strong healthcare reimbursement policies and a population increasingly receptive to advanced therapeutic options.
  • With biotechnology hubs in Toronto, Vancouver, and Montreal, Canada is well-positioned to support research and development initiatives.
  • The convergence of aging demographics, demand for personalized medicine, and technological advances in oral peptide delivery systems will sustain market expansion through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Canada's oral proteins & peptides market is valued at $88.2 million in 2025 and projected to reach $116.8 million by 2030.
    • Canada demonstrates a 5.8% CAGR, reflecting steady but moderate growth compared to global expansion rates.
    • Canada's mature healthcare system and regulatory framework support sustained adoption of oral peptide therapeutics.
    • Canada's market growth is driven by chronic disease prevalence, healthcare investment, and bioavailability technology advances.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Canada Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS37.75053.256.760.764.668.271.76.1
    HOSPITALS & SPECIALTY CLINICS1013.113.714.315.115.816.416.94.4
    LONG-TERM CARE FACILITIES15.220.121.322.624.225.626.928.25.7
    TOTAL62.983.188.293.7100106111.6116.85.8

    Target Audience

    • Pharmaceutical Companies : Identify market opportunities and regulatory pathways for launching oral peptide therapeutics in Canada, with insights into reimbursement landscapes and competitive positioning.
    • Biotech Investors : Evaluate investment potential in Canadian oral peptide companies with market sizing data, growth forecasts, and analysis of innovation hubs across Toronto, Vancouver, and Montreal.
    • Healthcare Consultants : Support strategic advisory services with Canada-specific market intelligence, regulatory frameworks, and trend analysis for clients entering or expanding in the oral peptide sector.
    • Nutraceutical Manufacturers : Understand market demand for oral peptide-based supplements and functional foods in Canada, including consumer preferences and distribution channel opportunities.
    • Government & Policy Makers : Leverage market data to inform healthcare policy, innovation incentives, and regulatory frameworks supporting Canada's oral peptide therapeutics industry development.

    Key Companies in the Canada Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Regulatory Intelligence : Gain detailed insights into Health Canada's approval pathways and regulatory requirements specific to oral peptide therapeutics, enabling faster market entry and compliance strategies.
    • Market Sizing & Forecasting : Access precise market valuation data for Canada ($88.2M in 2025) with granular 5-year forecasts to support investment decisions and resource allocation planning.
    • Competitive Landscape Analysis : Understand the competitive dynamics within Canada's oral peptide market, including key players, market share distribution, and emerging opportunities in pharmaceutical and nutraceutical segments.
    • Growth Driver Identification : Identify Canada-specific growth catalysts including healthcare infrastructure advantages, reimbursement policies, and demographic trends driving 5.8% CAGR expansion.
    • Strategic Market Entry : Develop targeted go-to-market strategies leveraging Canada's mature healthcare system, biotech innovation hubs, and favorable business environment for oral peptide product launches.

    Frequently asked questions

    What is the current size of Canada's oral proteins & peptides market?

    Canada's oral proteins & peptides market is valued at $88.2 million in 2025.

    What is the projected market size for Canada by 2030?

    Canada's oral proteins & peptides market is projected to reach $116.8 million by 2030.

    What is Canada's market growth rate for oral proteins & peptides?

    Canada's oral proteins & peptides market is expected to grow at a CAGR of 5.8% from 2025 to 2030.

    What factors are driving growth in Canada's oral proteins & peptides market?

    Growth in Canada is driven by rising healthcare expenditure, increasing chronic disease prevalence, advances in bioavailability technologies, and growing consumer awareness of peptide-based therapeutics.

    How does Canada's market compare to global oral proteins & peptides trends?

    Canada's 5.8% CAGR represents more moderate growth than the global 22.1% CAGR, reflecting Canada's mature market status and established healthcare infrastructure.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status